All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-09-17T08:43:38.000Z

Does current evidence support the use of MRD-guided treatment before transplant in patients with AML?

Sep 17, 2020
Share:

Bookmark this article

The virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of experts to discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future. Professor Adriano Venditti, University of Rome Tor Vergata, Rome, IT, presented the topic ‘Does current evidence support the use of MRD-guided treatment before transplant in patients with AML?’

Apart from being a predictor of outcomes in AML, MRD assessment prior to stem cell transplantation is emerging as an important indicator for therapeutic decision making. Professor Adriano Venditti discusses the results of ongoing clinical trials using an MRD-guided treatment approach and highlights the benefits of stem cell transplantation even in MRD-positive patients, especially those in a specific risk group.

The first AML Hub Satellite Symposium: Watch here!

Welcome to the AML Hub Satellite Symposium.

Please take a moment to complete the survey and answer the following question to help us gauge your current understanding of the use of MRD-guided treatment before transplant in patients with AML.

More about...

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox